Twist Bioscience Corp

TWST Nasdaq SEC CIK 1581280
Follow Twist Bioscience Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2026 USD · US GAAP
Revenue, last quarter $126.6M +27.9% vs same quarter last year
Net income −$20.6M +24% vs same quarter last year
EPS, diluted -
Operating cash flow −$173K +98.5% vs same quarter last year
Revenue by quarter
$88.7M
$92.8M
$96.1M
$99M
$103.7M
$110.7M
$118.4M
$126.6M
Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26 Q4 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income11 fiscal years
  • Revenue
  • Net income
−$400M−$200M$0$200M$400M$600MFY16FY18FY20FY22FY24FY26
Show the numbers
YearRevenueNet income
FY26$459.4M−$130.2M
FY25$376.6M−$77.7M
FY24$313M−$208.7M
FY23$245.1M−$204.6M
FY22$203.6M−$217.9M
FY21$132.3M−$152.1M
FY20$90.1M−$139.9M
FY19$54.4M−$107.7M
FY18$25.4M−$71.2M
FY17$10.8M−$59.3M
FY16--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−600%−400%−200%0%200%FY16FY18FY20FY22FY24FY26
Show the numbers
YearGross marginOperating marginNet margin
FY2652.4%−30.4%−28.3%
FY2550.7%−36.2%−20.6%
FY2442.6%−70.6%−66.7%
FY2336.6%−88.6%−83.5%
FY2241.4%−115.3%−107%
FY2139.1%−115.4%−114.9%
FY2031.8%−155.5%−155.3%
FY1912.8%−200.1%−198%
FY18−26.6%−277.5%−280.2%
FY17−123.1%−543.2%−550.8%
FY16---
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0FY16FY18FY20FY22FY24FY26
Show the numbers
YearFree cash flow
FY26−$89M
FY25−$75.6M
FY24−$69.2M
FY23−$170.3M
FY22−$226.2M
FY21−$139.3M
FY20−$152.1M
FY19−$102.7M
FY18−$69.9M
FY17−$57.9M
FY16-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Twist Bioscience
  • Healthcare median
−600%−400%−200%0%FY16FY18FY20FY22FY24FY26
Show the numbers
YearTwist BioscienceHealthcare median
FY26−28.3%−11.1%
FY25−20.6%−30.6%
FY24−66.7%−47%
FY23−83.5%−58%
FY22−107%−80.4%
FY21−114.9%−71.9%
FY20−155.3%−62.2%
FY19−198%−46.3%
FY18−280.2%−49.6%
FY17−550.8%−45.9%
FY16-−36%